In a welcome move, BeiGene ADR saw its Relative Strength Rating improve from 70 to 76 on Friday.
This proprietary rating identifies technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the top-performing stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if BeiGene ADR can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to offer and clear a proper buy point.
The company showed 0% EPS growth last quarter, while sales growth came in at 56%. The next quarterly numbers are expected on or around Nov. 12.
BeiGene ADR earns the No. 73 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
